---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-020494"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:48:29.294723+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics posts Q4 net income; aleniglipron up to 15.3% weight loss in Phase 2

## Summary
- Q4 2025 net income $33.0M vs. net loss of $36.5M in Q4 2024; full-year net loss $141.2M.
- Cash, equivalents and investments $1.4B as of Dec 31, 2025, funding through end of 2028.
- Aleniglipron Phase 2 ACCESS II: placebo-adjusted weight loss up to 15.3% with 240 mg at 36 weeks.
- Phase 3 for aleniglipron expected in H2 2026; topline 44-week data from ACCESS II due Q1 2026.
- Oral amylin agonists: ACCG-2671 in Phase 1; ACCG-3535 to enter Phase 1 in H2 2026.

## SEC filing metadata
- accession: 0001104659-26-020494
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465926020494/0001104659-26-020494-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465926020494/tm267321d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-020494
- JSON: https://secwatch.observer/filing/0001104659-26-020494.json
- Plain text: https://secwatch.observer/filing/0001104659-26-020494.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.